To date, the groundbreaking approval of the thyroid hormone receptor beta (THRβ) agonist resmetirom (MGL-3196) by the United States Food and Drug Administration (FDA) in 2024 represents the first-ever selective treatment for MASH. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.